Continuous glucose monitoring for cystic fibrosis-related diabetes: impact on quality of life and glycaemic control
Authors' conclusion
CGM use in CFRD improved QOL and glycaemic control without increases in hypoglycaemia.
Study context
- Population
- Insulin-requiring cystic fibrosis-related diabetes (cystic fibrosis related diabetes (CFRD))recruited
- Participants
- 19 participants
- Exposure
- Continuous glucose monitoring (CGM) for 3 months, baseline vs completion
- CGMn = 19
- Outcome
- HbA1c
- Follow-up
- Baseline to completion of intervention (3 months)
Main finding
As reported in the abstract
- Median HbA1c at baseline
- 8.7% (72 mmol/mol) (IQR:8-10.6%, 64-92 mmol/mol)
- Median HbA1c at completion of intervention
- 7.8% (62 mmol/mol) (IQR:7.3-8.3%, 56-67 mmol/mol)
- Change from baseline to completion
- p = 0.018
Observational data: associations, not effects.
Further findings
HbA1c 3 months post intervention · 3 months post completion
- Median HbA1c, remained lower than baseline
- 8.0% (64 mmol/mol) (IQR: 7.0-9.0%, 53-75 mmol/mol)
QOL: Problem Areas in Diabetes (PAID) score · baseline to completion of intervention
- Median PAID score at baseline
- 29.0 (IQR:16.0-48.5)
- Median PAID score at completion
- 16.0 (IQR: 11.0-22.0)
- Change from baseline to completion
- P = 0.02
PAID score 3 months post completion
- Median PAID score
- 19.0 (IQR 11.5-23.0)
Safety
Time spent <3.0 mmol/L · before vs after sensor use
- No increase in time <3.0 mmol/L, before vs after sensor use
- 0.0% vs 0.3% p = 0.50
Original publication
Continuous glucose monitoring for cystic fibrosis-related diabetes: impact on quality of life and glycaemic control. Diabetes Res Clin Pract. Published 20 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →